Genetic and environmental factors on the relation of lung function and arterial stiffness  by Tarnoki, David Laszlo et al.
Respiratory Medicine (2013) 107, 927e935Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate/rmedGenetic and environmental factors on the
relation of lung function and arterial
stiffnessDavid Laszlo Tarnoki a,*,m, Adam Domonkos Tarnoki a,m,
Zsofia Lazar b, Emanuela Medda c, Levente Littvay d,
Rodolfo Cotichini c, Corrado Fagnani c, Maria Antonietta Stazi c,
Lorenza Nistico´ c, Pierleone Lucatelli e, Emanuele Boatta e,
Chiara Zini e, Fabrizio Fanelli e, Claudio Baracchini f,
Giorgio Meneghetti f, Gyorgy Jermendy g, Istva´n Pre´da h,i,
Ro´bert Ga´bor Kiss h,i, Kinga Karlinger a, Agnes Lannert j,
Giuseppe Schillaci k, Andrea Agnes Molnar h,i, Zsolt Garami l,
Viktor Berczi a, Ildiko Horvath baDepartment of Radiology and Oncotherapy, Semmelweis University, 78/a Ulloi Street, Budapest 1082,
Hungary
bDepartment of Pulmonology, Semmelweis University, 1/C Dio´s a´rok, 1125 Budapest, Hungary
c Istituto Superiore Di Sanita´, National Centre for Epidemiology, Surveillance and Health Promotion,
Genetic Epidemiology Unit, Italian Twin Registry, Viale Regina Elena 299, 00161 Roma, Italy
dCentral European University, 9 Na´dor Street, 1051 Budapest, Hungary
eVascular and Interventional Radiology Unit, Department of Radiological Sciences, Sapienza University
of Rome, Viale Regina Elena 324, 00161 Roma, Italy
fDepartment of Neurosciences, School of Medicine, University of Padua, Via Giustiniani 5, 35128
Padova, Italy
gBajcsy Zsilinszky Hospital, 3rd Department of Internal Medicine, 89-91 Maglodi Street, Budapest 1106,
Hungary
hResearch Group for Inflammation Biology and Immunogenomics of Hungarian Academy of Sciences and
Semmelweis University, 44 Ro´bert Ka´roly krt, Budapest 1134, Hungary* Corresponding author. Tel.: þ36 30 3687843; fax: þ36 1 2780367.
E-mail addresses: tarnoki4@gmail.com (D.L. Tarnoki), tarnoki2@gmail.com (A.D. Tarnoki), zsofia.lazar@yahoo.com (Z. Lazar),
emanuela.medda@iss.it (E. Medda), levi@littvay.com (L. Littvay), rodolfo.cotichini@iss.it (R. Cotichini), corrado.fagnani@iss.it (C.
Fagnani), antonia.stazi@iss.it (M.A. Stazi), lorenza.nistico@iss.it (L. Nistico´), pierleone.lucatelli@gmail.com (P. Lucatelli), emanuele.
boatta@yahoo.it (E. Boatta), zini.chiara@gmail.com (C. Zini), fabrizio.fanelli@uniroma1.it (F. Fanelli), claudiobaracchini@tin.it (C.
Baracchini), giorgio.meneghetti@unipd.it (G. Meneghetti), gyjermendy@mail.datanet.hu (G. Jermendy), predadr@gmail.com (I. Pre´da),
robertgaborkiss@gmail.com (R.G. Kiss), kinga.karlking@gmail.com (K. Karlinger), zanzarita@freemail.hu (A. Lannert), skill@unipg.it (G.
Schillaci), molnandi@gmail.com (A.A. Molnar), ZGarami@tmhs.org (Z. Garami), berczi@hotmail.com (V. Berczi), kiss.horvath@t-online.hu
(I. Horvath).
m Each author contributed equally to this paper.
0954-6111/$ - see front matter ª 2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.rmed.2013.02.002
928 D.L. Tarnoki et al.iDepartment of Cardiology, Military Hospital e State Health Center, 44 Ro´bert Ka´roly krt, Budapest
1134, Hungary
j Semmelweis University, School of Pharmacy, 26 Ulloi Street, Budapest 1085, Hungary
kUnit of Internal Medicine, Department of Medicine, University of Perugia at Terni, Piazzale Tristano
di Joannuccio 1, 05100 Terni, Italy
lThe Methodist Hospital, Methodist DeBakey Heart & Vascular Center, 6565 Fannin Street, Houston, TX
77030, USAReceived 9 May 2012; accepted 7 February 2013
Available online 6 March 2013KEYWORDS
Pulmonary function
test;
Forced vital capacity;
Augmentation index;
Pulse wave velocity;
GeneticsSummary
Background: An association between reduced lung function and increased cardiovascular risk
has been reported, but the underlying mechanisms are unknown. The aim of this study was
to assess the heritability of lung function and to estimate its genetic association with arterial
stiffness.
Methods: 150 monozygotic and 42 dizygotic healthy Hungarian and American Caucasian twin
pairs (age 43  17 years) underwent spirometry (forced vital capacity/FVC/, forced expiratory
volume in 1 s/FEV1/; MIR Minispir, USA); and their brachial and central augmentation indices
(AIx), and aortic pulse wave velocity (PWV) were measured by oscillometric Arteriograph (Ten-
sioMed Ltd, Budapest, Hungary). Phenotypic correlations and bivariate Cholesky decomposi-
tion models were applied.
Results: Age-, sex-, country- and smoking-adjusted heritability of FEV1, percent predicted
FEV1, FVC and percent predicted FVC were 73% (95% confidence interval /CI/: 45e85%), 28%
(95% CI: 0e67%), 68% (95% CI: 20e81%) and 45% (95% CI: 0e66%), respectively. Measured and
percent predicted FVC and FEV1 values showed no significant phenotypic correlations with
AIx or aortic PWV, except for phenotypic twin correlations between measured FEV1, FVC with
brachial or aortic augmentation indices which ranged between 0.12 and 0.17. No genetic
covariance between lung function and arterial stiffness was found.
Conclusions: Lung function is heritable and the measured FVC and FEV are phenotypically, but
not genetically, associated with augmentation index, a measure of wave reflection. This rela-
tionship may in turn reveal further associations leading to a better mechanistic understanding
of vascular changes in various airway diseases.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Heritability of lung function has been investigated in twin
and family studies, with discordant results. In such studies,
heritability of forced expiratory volume in 1 s (FEV1)
ranged between 10% and 77% and that of forced vital ca-
pacity (FVC) ranged between 26% and 91%. Environmental
factors could explain a modest part of the variance in most
of the studies.1e5 Lung function also depends on gender.6
Age differences also influence the variance of lung func-
tion.3 A longitudinal study of twins found that the herita-
bility of FEV1 and FVC among never smoking female twins
do not change remarkably (32% and 36% for FEV1, 41% and
37% for FVC at baseline and at 3-year follow-up, respec-
tively).4 Genetic factors seem to modestly contribute to
lung function variance as demonstrated in a longitudinal
study.7
The relationship between impaired lung function and
atherosclerosis or cardiovascular morbidity and mortality
has been investigated by several authors.8,9 Higher arterial
stiffness is associated with poorer lung function whenadjusted for age, sex, and ethnic group.10 Elevated plasma
levels of inflammatory markers may partially explain the
increased cardiovascular risk among men with low FVC.11
Obviously, smoking also contributes to the association be-
tween pulmonary function and coronary heart disease.12
French epidemiological data showed that, even in healthy
men, there is a relationship between pulmonary function
and arterial stiffness.13 To our knowledge, no study has
ever investigated the genetic influence on the lung
function-arterial stiffness relationship. In order to assess
this association, twin study modeling is the most appro-
priate method. By comparing identical with non-identical
twins, twin studies provide information on the relative
contribution of genes and environment, and how the two
interact.
The aim of our study was to assess the heritability of
lung function, the phenotypic correlations between pul-
monary function (FEV1, FVC) and arterial stiffness mea-
sures, and furthermore, to determine whether there is a
shared genetic relation between lung function and arterial
stiffness.
Twin study on lung function and arterial stiffness 929Methods and materials
Subjects and study design
192 Hungarian and American healthy adult twin pairs (150
monozygotic [MZ] and 42 dizygotic [DZ]; age 43  17 years
(mean  standard deviation) were recruited in this classic
twin study. Exclusion criteria were chronic respiratory dis-
ease, pregnancy, ethnicity other than Caucasian, acute
infection within three weeks of measurement or foresee-
able lack of compliance with test procedures. Zygosity was
assigned according to a seven-part self-reported
response.14 Studies were approved by local ethical com-
mittees (Institutional Review Board committee names and
project approval numbers: Semmelweis University Regional
and Institutional Committee of Science and Research
Ethics, 29/2009; Twins Days Festival Ethical Board, 1/2009)
and all study subjects gave informed consent prior to
entering the study.
Anthropometric, respiratory and vascular measurements
were obtained at two Hungarian twin festivals (Agfalva and
Szigethalom), in two Hungarian hospitals and at the Twins
Days Festival in the USA (Twinsburg, OH) in 2009 and 2010.
Anthropometric data
Body mass index (BMI) was measured by a clinically vali-
dated OMRON BF500 body consistency monitor (Omron
Healthcare Ltd., Kyoto, Japan). Current height was verified
simultaneously.
Pulmonary function measurement
Lung function was assessed by dynamic spirometry (Minispir
Waukesha, WI, USA). The spirometer was calibrated daily
using a 1-L syringe. The maneuvers were performed with
the subject standing while wearing nose clips. The largest
FEV1 and the largest FVC from among all acceptable ma-
neuvers were used in this analysis. FVC and FEV1 mea-
surements were performed in accordance with guidelines
recommended by the American Thoracic Society.15 Lung
function variables were expressed in absolute (measured)
values and as a percentage of predicted values (based on
the subject’s age, height, sex), using the reference values
recommended by the ERS16 and ECCS93 reference equation
values.17
Arterial stiffness test
Aortic pulse wave velocity (PWVao) as a measure of arterial
stiffness and brachial (AIxbra) and aortic augmentation
indices (AIxao) as measures of the arterial waveform were
assessed by a clinically validated oscillometric device18,19
(TensioMed Arteriograph, TensioMed Ltd., Hungary, soft-
ware version 1.10.1.1.), calculating arterial stiffness pa-
rameters from oscillometrically recorded pressure waves
of the brachial artery (pulse wave analysis), in supine
position. PWVao is widely recognized as a direct marker
of arterial stiffness20,21 and inversely related to
arterial distensibility; it is calculated by the formula:PWVao Z distance (m)/transit time (sec). PWVao is corre-
lated with cardiovascular risk factors22 and it is a strong
vascular risk factor for prediction of mortality in the
elderly23 and in the general population.24 Dividing the
augmentation pressure (difference between the second and
first systolic peaks, P2eP1) by the pulse pressure gives the
augmentation index, which is an indirect marker of endo-
thelial dysfunction. The augmentation index is being used
more and more frequently in studies as a parameter of
peripheral vascular resistance and wave reflection.25,26
Study subjects were evaluated by the same researchers
in order to decrease inter-observer variability and in
accordance with guidelines recommended by the European
Society of Cardiology.27 The PWV is calculated from each
pulse wave from the suprasystolic measurement, and the
results are compared. The standard deviation of the PWV
values is taken as a measure of good correlation, or simi-
larity, between them. The software (TensioMed) accepts
the measurements as good quality under SDZ 1.0. Only the
mean value of the best measurement (if automatic quality
control showed less than 1.0 standard deviation for PWVao)
was taken into consideration during the analysis. All sub-
jects were restricted from smoking for 3 h, from eating for
1 h, and from drinking alcohol or coffee for 10 h prior to
measurements. Adherence to these restrictions was ascer-
tained by querying the subject.
Statistical analysis
Descriptive analysis (mean  standard deviation for
continuous variables, percentage for categorical variables)
for BMI, FEV1, FVC values, and vascular parameters was
conducted using SPSS (SPSS 17.0 for Windows; SPSS, Chi-
cago, IL). Differences between genders, zygosity and
countries were calculated using independent-sample t-
tests. P value <0.05 was considered significant. All analyzes
were corrected for age, gender, country (significant effect
of country, p < 0.05) and smoking (the phenotypic corre-
lations were also calculated unadjusted to smoking).
Smoking was adjusted according to two groups (never
smokers and ex-smokers with a quitting period of at least
one year and <5 pack year; and ex-smokers with >5 pack
year and active smokers; 1 pack year is defined as smoking 1
pack of cigarettes daily for at least one year). Heritability
estimates were determined based on the consideration that
greater levels of MZ than DZ within pair similarity indicate a
genetic influence on a phenotype, while similarity of
coetwin correlations suggests that the variance is due to
shared environmental factors. Three general sources of
variance are calculated: (i) additive genetic factors or
heritability (A) which represents the effects due to genes at
multiple loci or multiple alleles at one locus; (ii) common
environmental variance (C), which estimates the contribu-
tion of the common family environment of both twins
(familiar socialization, diet, exposure to high levels of air
pollution, parental smoking, shared womb, etc.); and (iii)
nonshared environmental variance (E), which represents
the effects that apply only to each individual twin and all
sources of unique experiences and exposures that cause
within-pair differences (e.g., discordance for smoking,
differences in illnesses and occupational exposures).
Structural equation modeling was performed using the
930 D.L. Tarnoki et al.Mplus Version 6.1 (Muthe´n&Muthe´n) weighted least squares
estimation due to the categorical variable of interest.28
Empirical confidence intervals were calculated with a
Bollen-Stine Bootstrap.29 Univariate quantitative genetic
modeling was performed to decompose the phenotypic
variance of the considered parameters into heritability (A),
shared (C), and unshared (E) environmental effects (ACE
analysis).30 Chi-square model fit p-values are presented
where the desired results show insignificant model misfit.
Instead of a covariance matrix, the estimation procedure
used the raw data matrix. Given the small sample size, no
component was fixed to 0 in the model.
A bivariate Cholesky decomposition was used to derive
the magnitude of covariation between the investigated
respiratory function and arterial stiffness phenotypes and
to estimate what proportion of this correlation is attribut-
able to common underlying genetic and environmental
factors. In order to estimate the amount of overlap be-
tween genes or environment that influences the two pa-
rameters, genetic and environmental correlations between
those phenotypes were calculated.
Results
Clinical characteristics and measures
Table 1 presents clinical characteristics of the sample by
zygosity, sex and country. Opposite-sex twin pairs were
excluded as their inclusion could bias the heritability esti-
mates upward if gender-specific or X chromosome effects
are present. A significant difference between males and
females was observed concerning the arterial stiffness,
BMI, measured FEV1 and FVC (p < 0.05 for all). A significant
difference in the rate of current and ex-smokers was
detected across countries (p < 0.001 for both). Smoking
years were higher in dizygotic twins than in monozygotic
subjects (p < 0.05). Significant differences were observed
in pulmonary function parameters concerning zygosity
(p < 0.05) except for percent predicted FEV1. Hungarian
twins had significantly higher lung function values
(p < 0.001 for FVC and p < 0.05 for FEV1, respectively)
compared to the Americans.
Heritability analysis of pulmonary function and
arterial stiffness
Age-, sex-, country- and smoking-adjusted genetic and
environmental variance, estimated with ACE analysis, and
demonstrated 95% confidence intervals (CI), are shown in
Table 2. Accordingly, genetic factors appear to contribute,
at least in part, to the pulmonary function and arterial
stiffness parameters, as the MZ twins had higher intrapair
correlation compared to that of DZ twins. Models had a
good fit.
Phenotypic twin correlations between pulmonary
function and arterial stiffness
Table 3 presents phenotypic twin correlations, the corre-
lations between phenotypes within the same individuals,for FEV1, FVC and arterial stiffness considering age, family,
sex and country as covariates with or without smoking
adjustment. Phenotypic correlation ranged between 0.12
and 0.17 (p < 0.05) between measured pulmonary func-
tion values and both brachial and aortic augmentation
indices, suggesting that better measured lung function
corresponds to lower AIx values. Additionally, FVC and FEV1
values showed no significant phenotypic correlations with
AIx or aortic PWV. The estimated ACE model confirmed the
role of genetic factors on lung function and arterial stiff-
ness phenotypes; in addition, significant low phenotypic
correlations were estimated between some pulmonary
function and arterial stiffness measures, therefore, a
possible genetic covariance of FEV1, FVC and AIx can be
estimated by the bivariate Cholesky decomposition model.
Measured and percent predicted FVC and FEV1 values
showed no significant phenotypic correlation with aortic
PWV; therefore, the influence of common genetic and
environmental factors on those relationships were not
investigated.
Genetic covariance of FEV1, FVC, brachial and
aortic augmentation indices
Standardized genetic, common and unique environmental
components of the covariance were calculated in the
investigated measures by the bivariate Cholesky decom-
position model. Additive genetic components showed no
significant influence for the covariance between lung
function values and augmentation indices (therefore, data
are not shown).
Discussion
To our knowledge, this is the first study that investigates
the relative contribution of genetic and environmental
factors to the relation between lung function and arterial
stiffness in a relatively large twin sample. This study
demonstrates that the heritability of lung function is high
for observed absolute values and moderate for percent
predicted values, and a significant negative low phenotypic
correlation exists between measured FEV1, FVC and
augmentation indices. No significant phenotypic correlation
was estimated between lung function parameters and
aortic PWV. No genetic covariance was found between
FEV1, FVC and augmentation index.
Our findings concerning the heritability of lung function
and vascular stiffness are in line with the liter-
ature.1e3,30e37 In our population-based sample of twins,
genetic effects accounted for 28e73% of the variability of
lung function. Two twin studies showed that additive ge-
netic effects on FEV1 accounted for 61%, and 67% of the
total variation; however, the mean age was higher with
respect to our population.1,3 Hubert and co-workers re-
ported slightly higher heritability results than our data, but
their study population contained only adult (42e56 years)
male twins.2 The genetic variance accounted for 50e58%
for the brachial AIx, aortic AIx and PWV, similarly to other
studies with reported heritabilities of 37e53%.30e34
Significant negative phenotypic correlation was found
between FEV1, FVC and AIx (but not with aortic PWV) which
Table 1 Clinical characteristics and measures according to zygosity, gender and country.
Total Zygosity Gender Country
Monozygotic Dizygotic Male Female Hungarian American
Subjects, n 384 300 84 88 296 290 94
Monozygotic:dizygotic, n 300:84 N/A N/A 70:18 230:66 212:78 88:6
Age, years 43  17 42  17% 48  14% 43  17 44  17 43  17 46  17
FVC, % predicted 97.4  16.0 96.1  16.3% 100.6  14.9% 99.3  16.1 96.7  16.0 100.0  15.0x 89.1  16.2x
FEV1, % predicted 99.3  15.5 98.8  15.7 100.5  15.0 99.1  17.5 99.2  14.8 100.3  14.9# 95.9  16.9#
FEV1, l 3.0  0.8 2.9  0.8% 3.1  0.9% 3.8  0.8$ 2.7  0.6$ 3.1  0.8x 2.7  0.8x
FVC, l 3.5  1.0 3.4  1.0U 3.8  1.1U 4.6  1.0$ 3.2  0.7$ 3.7  1.0x 3.0  0.9x
Brachial AIx, % 29.6  32 30.5  33 26.0  29 43.3  26y 25.6  33y 29.0  32 31.3  30
Central AIx, % 22.5  16 22.0  16 24.2  14 15.6  13y 24.5  16y 22.7  16 21.8  15
Aortic PWV, m/s 8.6  2.5 8.4  2.4 9.3  2.4 8.1  2.0y 8.8  2.6y 8.7  2.5 8.6  2.4
BMI, kg/m2 25.8  5.5 25.6  5.5 26.6  5.4 27.0  4.5y 25.6  5.8y 25.4  5.2^ 27.4  6.2^
Never smokers, % 70.3 71.4 66.3 67.4 71.1 70.5 69.5
Ex smokers, % 17.1 16.2 20.5 19.1 16.5 13.7x 27.4x
Current smokers, % 12.6 12.5 13.3 13.5 12.4 15.8x 3.2x
Smoking years 4.3  9.7 3.5  8.3% 7.3  13.3% 5.1  10.4 4.1  9.4 4.3  9.5 4.3  10.2
Mean  standard deviation. FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; AIx, augmentation index; PWV, pulse wave velocity; BMI, body mass index.
%Monozygotic vs dizygotic p < 0.05.
UMonozygotic vs dizygotic p < 0.005.
yMale vs female p < 0.05.
$Male vs female p < 0.001.
^Hungarian vs American p Z 0.052.
x Hungarian vs American p < 0.001.
#Hungarian vs American p < 0.05.
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Table 2 Age, gender, country and smoking adjusted genetic and environmental variance component parameter estimates and
95% confidence intervals of the best-fitting univariate ACE models with p value of model fit.
Measure A C E Model fit (p value)
FVC, % predicted 0.45 (0.00e0.66) 0.14 (0.00e0.56) 0.41 (0.31e0.52) 0.58
FEV1, % predicted 0.28 (0.00e0.67) 0.31 (0.00e0.59) 0.41 (0.27e0.55) 0.49
FVC, l 0.68 (0.20e0.81) 0.08 (0.00e0.55) 0.24 (0.17e0.32) 0.49
FEV1, l 0.73 (0.45e0.85) 0.00 (0.00e0.55) 0.26 (0.17e0.37) 0.26
Aortic AIx, % 0.58 (0.10e0.75) 0.10 (0.00e0.57) 0.32 (0.24e0.44) 0.12
Brachial AIx, % 0.55 (0.08e0.74) 0.13 (0.00e0.57) 0.33 (0.24e0.45) 0.17
Aortic PWV, m/s 0.50 (0.25e0.68) 0.00 (0.00e0.00) 0.50 (0.33e0.73) 0.0001
A, indicates heritability; C, shared environmental variance component; E, unique environmental variance component; Model fit, p value
of Chi-square test of Model fit; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; AIx, augmentation index; PWV, pulse
wave velocity.
932 D.L. Tarnoki et al.indicates that impaired lung function is associated with
increased peripheral vascular resistance and wave reflec-
tion, but not with aortic distensibility characterized by
aortic PWV. The association of cardiovascular and respira-
tory system has been previously hypothesized because
increased cardiovascular morbidity and mortality was
observed in patients with impaired lung function.8e10
However, novel hemodynamic measurements such as
oscillometric arterial stiffness assessment, which is
included in our study, had not been previously performed.
Our study showed that there is a phenotypic but no genetic
relationship between lung function and peripheral vascular
resistance (wave reflection). AIx is accepted as measure of
wave reflection30 and it is closely correlated with the car-
diovascular risk and an independent predictor of mortality
in patients with end-stage renal disease.26 Arterial stiffness
was also correlated with the quality of life in older
people.35
Although we report data collected from a healthy pop-
ulation, the relationship between arterial stiffness and
respiratory diseases, such as chronic obstructive pulmonary
disease (COPD) and bronchial asthma, might also be of
clinical relevance and has in fact been investigated pre-
viously.36e44 In particular, COPD and emphysema patients
are at increased risk for cardiovascular morbidity and
mortality, associated with endothelial dysfunction, arterial
stiffness and atherogenesis, independently of tobaccoTable 3 Bivariate family, age, sex, population corrected phenot
smoking adjustment from a bivariate structural equation satura
tween lung function and arterial stiffness parameters.
Brachial AIx, %
Non smoking adjusted FVC, % predicted 0.038 (0.079, 0.
FEV1, % predicted 0.011 (0.107, 0.
FVC 0.147* (0.267, 
FEV1 0.162* (0.281, 
Smoking adjusted FVC, % predicted 0.063 (0.055, 0.
FEV1, % predicted 0.040 (0.078, 0.
FVC 0.121 (0.243, 0.
FEV1 0.133* (0.254, 
AIx, augmentation index; PWV, pulse wave velocity; FVC, forced vita
*p < 0.05.smoke exposure.36e40 The key elements causing an early
subclinical cardiovascular involvement in COPD patients
may include systemic and abnormal lung inflammation,
hypoxia, oxidative stress, alterations in levels of matrix
metalloproteinases and the functionality of endothelial
nitric oxide synthase.41,42 Emphysema severity is associated
with arterial stiffness in COPD patients, which may be
attributable to similar pathophysiological processes within
the lung and arteries.43 Significant correlations between
arterial stiffness and FEV1 were reported in asthmatic pa-
tients, suggesting the presence of a common systemic
process, most likely an inflammatory pathway, involving
both the cardiovascular and respiratory systems.44
Based on our results, the same non-genetic factors may
play a role in lung function and endothelial function in
healthy individuals.11e13 Due to the possible non-genetic
(although weak) link between impaired lung function and
vascular resistance, as a possible clinical consequence of
our study, early screening of augmentation index in pa-
tients with reduced lung function is warranted. Similarly, a
recent prospective study reported that lung function
assessment in mid-life may identify individuals at greater
risk of future cardiovascular disease.45 Augmentation index
could be non-invasively assessed at an early age in healthy
subjects with impaired lung function who are still free of
respiratory illnesses, and conversely, pulmonary function
could be assessed in subjects with increased augmentationypic correlations and 95% confidence intervals with or without
ted model of a genetic covariance decomposition model be-
Central AIx, % Aortic PWV, m/s
156) 0.037 (0.081, 0.155) 0.030 (0.145, 0.085)
129) 0.009 (0.109, 0.128) 0.055 (0.172, 0.061)
0.027) 0.150* (0.271, 0.030) 0.000 (0.120, 0.119)
0.043) 0.166* (0.285, 0.046) 0.007 (0.128, 0.115)
181) 0.062 (0.056, 0.180) 0.017 (0.134, 0.099)
159) 0.039 (0.080, 0.157) 0.041 (0.160, 0.077)
001) 0.123 (0.246, 0.001) 0.012 (0.108, 0.133)
0.012) 0.126* (0.246, 0.006) 0.009 (0.114, 0.131)
l capacity; FEV1, forced expiratory volume in 1 s.
Twin study on lung function and arterial stiffness 933indices or atherosclerotic phenotypes if further studies
confirm our results. To our knowledge, no previous study
has investigated the relationship between PWV and lung
function in healthy subjects; nonetheless, other authors
reported higher PWV in the case of impaired lung function
in chronic respiratory diseases.37,39,43,44
Our cohort consisted of healthy middle-aged individuals
whomay present endothelial dysfunction (increased AIx) but
normal aortic PWV, which is mainly accelerated in advanced
atherosclerosis in older age.46 Of note, the mean aortic PWV
value was not elevated in our sample. A correlation between
impaired pulmonary function and elevated AIx but not with
aortic PWV could be explained if our study population had
subclinical atherosclerosis with increased Aix, which was not
significant enough to result in increased aortic PWV. We
suppose that this argument may serve as a possible inter-
pretation for the discrepancy between the AIx and PWV
findings. In addition, it must be noted that the statistical test
(genetic covariance composition) traditionally calls for a
large sampling in comparison to our sample size. This could
be the reason why our results concerning the covariance
analysis are not statistically significant.
The strength of our study is underpinned by the evalu-
ation of all the lung function and arterial stiffness tests that
were performed by the same trained researchers, with the
same devices, on the same day. However, as in every
human clinical study, there are unavoidable limitations.
Data were pooled across countries to raise the power to
identify genetic and environmental effects but no evidence
of heterogeneity between states was detected.
In conclusion, our study was the first international twin
study to investigate the possible genetic relationship be-
tween lung function and arterial stiffness. Our data suggest a
phenotypic but not genetic link between lung function and
peripheral vascular resistance (wave reflection). This rela-
tionship may explain the importance of inflammation,
oxidative stress and hypoxia in the pathogenesis of athero-
genesis. Improved understanding of the factors associated
with increased cardiovascular risk in the setting of lung
function impairment is needed. Our study could be a first
step to find further associations of vascular changes in
different airway diseases and help guide linkage studies to-
ward better understanding of the cardiopulmonary system.
Improved understanding of the factors associated with
increased cardiovascular risk in the setting of lung function
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